Physician profile
Sjoerd Beck
NPI 1477514016
$406.40
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $406.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $90.12 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.53 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $72.42 | 2019 | |
| Sunovion Pharmaceuticals INC. | $53.64 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $19.11 | 2019 | |
| Fisher & Paykel Healthcare INC | $18.20 | 2019 | |
| Resmed Corp | $17.78 | 2019 | |
| Mylan Specialty L.P. | $16.15 | 2019 | |
| Mallinckrodt Enterprises LLC | $16.11 | 2019 | |
| Shire North American Group INC | $14.77 | 2019 | |
| Grifols USA, LLC | $13.57 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sjoerd Beck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.